Text Size

Bimatoprost/Timolol Versus Travoprost/Timolol

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Tamer A Macky, Kasr El Aini Hospital
ClinicalTrials.gov Identifier:
NCT01542710
First received: February 6, 2012
Last updated: March 1, 2012
Last verified: January 2011
History of Changes
  Purpose

The purpose of this study is to compare 2 fixed combination medications in intraocular pressure lowering.


Condition Intervention
Glaucoma
 Drug: Ganfort
Drug: Duotrav

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Bimatoprost/Timolol Versus Travoprost/Timolol Fixed Combinations in an Egyptian Population: A Hospital-Based Prospective Randomized Study

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by Kasr El Aini Hospital:

Primary Outcome Measures:
  • Percentage of drop of intraocular pressures from baseline. [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]

Enrollment: 80
Study Start Date: January 2011
Study Completion Date: December 2011
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Glaucoma fixed Combination Medications Drug: Ganfort
Bimatoprost/Timolol fixed combination
Other Name: Bimatoprost/Timolol vs Travoprost/Timolol fixed combination
Drug: Duotrav
Fixed combination of Travoprost and Timolol

Detailed Description:

PURPOSE: To compare the efficacy of bimatoprost/timolol (BTFC) or travoprost/timolol (TTFC) fixed combinations on intraocular pressure (IOP) reduction in an Egyptian population.

METHODS: Patients with primary open angle glaucoma (POAG) were randomized to receive either BTFC or TTFC. IOPs were measured at baseline, 2 weeks, and 1, 2, 4, and 6 months. The primary outcome measures were the mean change in IOP from baseline

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Glaucoma

Exclusion Criteria:

  • No other ocular diseases
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01542710

Locations
Egypt
Kasr El Aini Hospital
Cairo, Egypt
Sponsors and Collaborators
Kasr El Aini Hospital
Investigators
Principal Investigator: Tamer A Macky, MD FRCS Cairo University
  More Information

No publications provided

Responsible Party: Tamer A Macky, Assistant Professor, Kasr El Aini Hospital
ClinicalTrials.gov Identifier: NCT01542710     History of Changes
Other Study ID Numbers: Fixed Glaucoma Medications, GFDU-2011, GANDUO-2011
Study First Received: February 6, 2012
Last Updated: March 1, 2012
Health Authority: Egypt: Institutional Review Board

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases
Timolol
Travoprost
Bimatoprost
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
 Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Antihypertensive Agents

ClinicalTrials.gov processed this record on May 22, 2013